Afuco™ Anti-GD3 Ganglioside ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-131) (CAT#: AFC-TAB-131)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to GD3 ganglioside. It is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Chimeric
- Derivation
- Chimeric (mouse/human)
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- FC, IP, ELISA, Neut, FuncS, IF
- Conjugate
- Unconjugated
- Generic Name
- Ecromeximab
- Related Disease
- Malignant melanoma
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- GD3 ganglioside
Related Resources
Please refer to Ecromeximab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Ecromeximab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Ecromeximab"
DrugMonitor™ Anti-Ecromeximab Antibody (VS-1224-YC388)Ecromeximab targets GD3-positive cells to initiate antibody-dependent cytotoxicity against these cells, studied for treating cutaneous and metastatic melanoma. The DrugMonitor™ Anti-Ecromeximab Antibody (VS-1224-YC388) is an anti-drug antibody (ADA) against Ecromeximab. This drug-based antibody is raised in mice immunized with the Ecromeximab. The anti-Ecromeximab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Ecromeximab in samples.
See other products for "GD3 ganglioside"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single Domain Antibody Products
Chimeric Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NAB-1058-VHH | Recombinant Anti-Human GD3 ganglioside VHH Single Domain Antibody | IHC, ICC, IP, ChiP, Neut | Llama VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-131. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: WB, ELISA, FC, IP, FuncS, IF, Neut
-2.png)
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: ELISA, SPR, Inhib, FuncS
Application: IHC, ELISA, FC, WB, ADCC, FuncS
-3.jpg)
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: Neut, FuncS, IHC, ELISA, FC, Inhib
Application: ELISA, Block, WB, FC, IP
Application: ELISA, FC, FuncS
Application: ELISA, Inhib, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
